Matsalar: Ƙarfin Hannu Yana Raguwa Fiye da Kwarin Zukatan Mutane
Sarcopenia, wato ragin ƙwanƙolin tsoka da aikin ta da ke faruwa tare da tsufa, yana ɗaya daga cikin ɓoyayyun matsalolin da ba a cika magana a kai ba a cikin al'umma. Ba ya bayyana a fili, amma yana sanya buɗe leda ya zama wahala, matakai sukan zama kamar tudu, kuma tafiya da aka ɗauka a matsayin sauƙi yanzu tana buƙatar ƙoƙari. Horon da ke ƙunshe da ɗagawa (resistance training) shi ne mafi inganci don rage wannan matsala, amma ba kowa ke da dama ko ƙarfi don ɗaga nauyi mai nauyi ko yin horo akai‑akai ba. Rashin ƙarfi, ciwon gwiwa, cututtuka masu ɗorewa, da rashin samun damar horo suna ƙara tsananta lamarin. Wannan ya sa masu bincike ke neman ƙarin kari da za su iya taimakawa waɗanda ba su da damar yin horo sosai.
Wani sabon gwaji na bazuwar da aka wallafa a Archives of Gerontology and Geriatrics ya gwada ɗaya daga cikin irin waɗannan kari: fucoidan mai ƙananan kwayoyi da aka fitar daga algae mai launin ruwan kasa. Sakamakon ya nuna alƙawari a bangaren ƙarfi da aikin jiki, amma ba a samu ƙaruwa a girman tsoka ba.
Menene Oligo‑Fucoidan?
Fucoidan wani sulfated polysaccharide ne da ake samu a algae mai launin ruwan kasa, kuma an dade ana nazarin tasirinsa a fannoni da dama, ciki har da yiwuwar taimakawa tsoka. Samfurin da aka yi amfani da shi a wannan gwaji shi ne nau'in "oligo", wato an warware shi zuwa ɓangarori ƙananan da ke da kusan 15 kDa. Manufar ita ce ƙananan kwayoyi su fi sauƙin shigowa jiki. Gwajin ya yi amfani da samfurin da aka yi alama da OliFuco, don haka sakamakon ya shafi wannan ƙayyadaddun tsari ne kawai, ba dukkan fucoidan ko kowane kari na algae ba.
Yadda Gwajin Ya Gudana
Gwajin makonni 12, ne‑blind, placebo‑controlled, ya haɗa da mutane 60 da suka kai shekara 60 ko fiye, tare da rarrabasu zuwa rukuni uku:
- Oligo‑Fucoidan kadai
- Oligo‑Fucoidan tare da branched‑chain amino acids (BCAAs) da bitamin D
- Placebo
Adadin fucoidan da aka ba kowane mahalarta shi ne miligram 825 sau biyu a rana, wato miligram 1,650 a kowace rana. An auna ƙarfin riƙe da hannu (handgrip strength), diamita na ƙafafu (calf circumference), ƙimar ƙwanƙolin tsoka (appendicular lean mass index – DXA‑style), gwajin tsayawa da zaune sau biyar, gwajin tafiya na minti 6 (6MWT) da ƙarfin fitar da gwiwa (isokinetic knee extension strength). Tabbatarwar ƙarshe ta nuna cewa an yi nazari a kan mahalarta 46. Abstrakt ɗin ba ya ƙunshe da wani shiri na motsa jiki, don haka sakamakon za a ɗauke su a matsayin tasirin kari ne a rayuwar yau da kullum, ba a sakamakon wani sabon horo ba.
Sakamakon Da Ya Fice: Ƙarfin Riƙe da Hannu
Ƙarfin riƙe da hannu ya ƙaru sosai a rukuni na Oligo‑Fucoidan (p < 0.001, effect size r = 0.82). A cikin wannan rukuni, kashi 64.7 % na mahalarta sun wuce ƙaramar bambanci da ke da mahimmanci a kiwon lafiya – wato canjin ya isa ya zama abin lura a rayuwar yau da kullum. Rubutun Ergo‑Log ya ƙara da cewa an samu ƙaruwa kusan 18‑23 %, amma wannan adadi yana fitowa ne daga ƙididdigar biyu, ba daga abstrakt ba.
Ƙarfin riƙe da hannu ba wasa ba ne kawai; ana amfani da shi a matsayin alamar gaggawa ga yanayin tsoka gaba ɗaya a manya, kuma yana daga cikin muhimman abubuwan da ake dubawa wajen tantance sarcopenia. Don haka samun ci gaba mai ma'ana a cikin makonni 12 abu ne da ya kamata a yaba.
Aikin tafiya ma ya inganta. Nisan tafiya a 6MWT ya ƙaru sosai (p < 0.001), kuma kashi 47.1 % na mahalarta sun wuce ƙaramar canjin da za a iya ganowa. Binciken MANOVA (multivariate analysis) kan manyan sakamako shida ya nuna bambanci mai ma'ana tsakanin rukuni‑rukuni, inda mafi yawansu suka samu ci gaba ne daga ƙaruwa a ƙarfin riƙe da hannu na rukuni na fucoidan idan aka kwatanta da placebo.
Abubuwan Da Suka Sha Baya: Babu Ƙaruwa a Tsoka, BCAAs + Vitamin D Ba Su Da Ƙarin Fa'ida
Akwai abubuwa biyu da suka ƙara rikitar da labarin.
Yawan tsoka ba ta canza ba – Fa'idar ta bayyana ne a ƙarfi da aikin jiki, ba a girman ƙwanƙolin tsoka ba. Wannan na iya nufin fucoidan yana aiki kan ingancin ƙwayoyin tsoka, aikin jijiyoyi, ko wani abu daban, amma gwajin bai iya tantance hakan ba. Alamar da ta shafi nauyin tsoka ta fito ne a rukuni na placebo, inda girman ƙafafu ya ragu (p = 0.012), yayin da rukuni na fucoidan ba ya nuna irin wannan raguwa.
BCAAs da bitamin D ba su ƙara fa'ida ba – Yawancin masu haɗa kari suna tunanin cewa ƙara amino acid da bitamin zai ƙara tasiri, amma gwajin bai nuna wani ƙarin amfani ba idan aka kwatanta da fucoidan kadai.
Babu wani rahoton illa mai tsanani a cikin wannan tsari na makonni 12.
Ƙalubale Masu Mahimmanci
Wannan ƙaramar gwaji ne: mutane 60 da aka raba su zuwa rukuni uku, kuma ya tsaya makonni 12 kacal. Saboda haka ba mu san ko ci gaban zai ci gaba, ya tsaya ko ya ragu ba. Hakanan samfurin da aka yi amfani da shi alama guda ɗaya ne, mai ƙananan kwayoyi, a daidaitaccen adadi – ba za mu iya ɗauka cewa duk wani fucoidan zai yi aiki daidai ba. Marubutan sun yi kira ga ƙarin bincike kan dogon lokaci da inganta tsarin samfurin. Gwaje‑gwajen ƙanana da ke da tasiri mai girma dole ne a maimaita su kafin a ɗauke su a matsayin gaskiya.
Abubuwan Da Za a Iya Amfani Da Su a Rayuwa
- Waɗanda za su iya amfana: manya, musamman waɗanda ba su da ƙarfi ko damar yin horon ƙarfi mai tsanani.
- Adadin da aka gwada: miligram 825 sau biyu a rana (miligram 1,650 a kowace rana) na Oligo‑Fucoidan mai ƙananan kwayoyi, tsawon makonni 12.
- Kada ku yi tsammanin ƙarin tsoka: an auna ƙarfin riƙe da hannu da aikin tafiya, ba girman tsoka ba.
- Rage ƙarin sinadarai a yanzu: BCAAs da bitamin D ba su ƙara fa'ida ga fucoidan a wannan gwaji ba.
- Horon ƙarfi har yanzu yana da muhimmanci: marubuta sun tabbatar da cewa horon ƙarfi shi ne hanya mafi tasiri. Idan kuna iya ɗaga nauyi, ku ci gaba da yi. Fucoidan, idan ya tabbatar, zai iya zama ƙari ko madadin, ba zai maye gurbin horo ba.
- Nemi shawara daga likita: duk wanda ke da cuta ko ke shan magani ya kamata ya tuntuɓi ƙwararren lafiya kafin ƙara wani kari.
Gabaɗaya
Wannan gwaji ya nuna cewa fucoidan da aka samo daga algae na iya ƙara ƙarfin riƙe da hannu da nisan tafiya a manya cikin watanni uku, ba tare da wani rahoton illa mai tsanani ba. Wannan yana nuni da wata hanya mai alheri, ba magani ba, ga masu fuskantar ƙalubalen horo. Sai dai har yanzu yana da ƙananan girma, an yi amfani da samfur na musamman, kuma ba a samu ƙaruwa a yawan tsoka ba. Don haka a ɗauke shi a matsayin alamar da za a bi, ba a matsayin maye gurbin horon ƙarfi ba.
Source: Chang et al. "The effects of Oligo‑Fucoidan on muscle function in community‑dwelling older adults: A double‑blind, randomized, placebo‑controlled trial." Archives of Gerontology and Geriatrics (2026). DOI: 10.1016/j.archger.2025.106055. PubMed: 41124892.
